Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Dysregulation of the complement system is implicated in neurodegeneration, including human and animal glaucoma. Optic nerve and retinal damage in glaucoma is preceded by local complement upregulation and activation, but whether targeting this early innate immune response could have therapeutic benefit remains undefined. Because complement signals through three pathways that intersect at complement C3 activation, here we targeted this step to restore complement balance in the glaucomatous retina and to determine its contribution to degeneration onset and/or progression. To achieve this, we combined adeno-associated virus retinal gene therapy with the targeted C3 inhibitor CR2-Crry. We show that intravitreal injection of AAV2.CR2-Crry produced sustained Crry overexpression in the retina and reduced deposition of the activation product complement C3d on retinal ganglion cells and the inner retina of DBA/2J mice. This resulted in neuroprotection of retinal ganglion cell axons and somata despite continued intraocular pressure elevation, suggesting a direct restriction of neurodegeneration onset and progression and significant delay to terminal disease stages. Our study uncovers a damaging effect of complement C3 or downstream complement activation in glaucoma, and it establishes AAV2.CR2-Crry as a viable therapeutic strategy to target pathogenic C3-mediated complement activation in the glaucomatous retina.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Jonas, J. B., Aung, T., Bourne, R. R., Bron, A. M., Ritch, R., & Panda-Jonas, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31469-1 · Cited by 1,322
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Vitamin B 3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice
Williams, P. A., Harder, J. M., Foxworth, N. E., Cochran, K. E., Philip, V. M., Porciatti, V., Smithies, O., & John, S. W. M. (2017) · Science · doi:10.1126/science.aal0092 · Cited by 617
Howell, G. R., Macalinao, D. G., Sousa, G. L., Walden, M., Soto, I., Kneeland, S. C., Barbay, J. M., King, B. L., Marchant, J. K., Hibbs, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44646 · Cited by 473
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Self-citationDistal axonopathy with structural persistence in glaucomatous neurodegeneration
Crish, S. D., Sappington, R. M., Inman, D. M., Horner, P. J., & Calkins, D. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913141107 · Cited by 350
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Self-citationNeuroinflammation in glaucoma: A new opportunity
Williams, P. A., Marsh-Armstrong, N., Howell, G. R., Bosco, A., Danias, J., Simon, J., Di Polo, A., Kuehn, M. H., Przedborski, S., Raff, M., et al. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.02.014 · Cited by 253
Self-citationC1q: A fresh look upon an old molecule
Thielens, N. M., Tedesco, F., Bohlson, S. S., Gaboriaud, C., & Tenner, A. J. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.025 · Cited by 237
Microarray analysis of retinal gene expression in the DBA/2J model of glaucoma
Steele, M. R., Inman, D. M., Calkins, D. J., Horner, P. J., & Vetter, M. L. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0865 · Cited by 196
Self-citationRadu, R. A., Hu, J., Yuan, Q., Welch, D. L., Makshanoff, J., Lloyd, M., McMullen, S., Travis, G. H., & Bok, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.191866 · Cited by 157
Cashman, S. M., Ramo, K., & Kumar-Singh, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019078 · Cited by 118
Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108
Neuroprotection for glaucoma: Requirements for clinical translation
Levin, L. A., Crowe, M. E., Quigley, H. A., Cordeiro, M. F., Donoso, L. A., Liao, Y. J., Libby, R. T., Masland, R. H., Nickells, R. W., Sieving, P. A., et al. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2016.12.005 · Cited by 66
Cited by
Sterling, J. K., Adetunji, M. O., Guttha, S., Bargoud, A. R., Uyhazi, K. E., Ross, A. G., Dunaief, J. L., & Cui, Q. N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108271 · Cited by 148
Margeta, M. A., Yin, Z., Madore, C., Pitts, K. M., Letcher, S. M., Tang, J., Jiang, S., Gauthier, C. D., Silveira, S. R., Schroeder, C. M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.014 · Cited by 130
More than meets the eye: The role of microglia in healthy and diseased retina
Murenu, E., Gerhardt, M.-J., Biel, M., & Michalakis, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006897 · Cited by 73
Mashal, M., Attia, N., Martínez-Navarrete, G., Soto-Sánchez, C., Fernández, E., Grijalvo, S., Eritja, R., Puras, G., & Pedraz, J. L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.010 · Cited by 58
Microglia phagocytic mechanisms: Development informing disease
Beiter, R. M., Sheehan, P. W., & Schafer, D. P. (2024) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102877 · Cited by 44
Metadata
- Authors
- Bosco, A., Anderson, S. R., Breen, K. T., Romero, C. O., Steele, M. R., Chiodo, V. A., Boye, S. L., Hauswirth, W. W., Tomlinson, S., & Vetter, M. L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 26
- Issue
- 10
- Pages
- 2379-2396
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2883705083
- Cited by
- 110
- References
- 17
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.